Research & Markets: Par Pharmaceutical Boosted its Position in the US Market Through the Purchase of a Number of Drugs from Teva and IVAX.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49747) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: "Par Pharmaceutical Generics Company Intelligence Report" to their offering. Our generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA ANDA abbr. abbreviated new drug application approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . Par Pharmaceutical was founded in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of in 1978. Many products are licensed-in from other generic manufacturers, such as Genpharm or Spectrum, or originator companies. Par has concluded a number of authorised generic agreements with originators, most recently with AstraZeneca for metoprolol metoprolol /met·o·pro·lol/ (met?ah-pro´lol) a cardioselective ß used in the form of the succinate and tartrate salts in the treatment of hypertension, chronic angina pectoris, and myocardial infarction. ER. Par's in-house manufacturing capabilities revolve re·volve v. re·volved, re·volv·ing, re·volves v.intr. 1. To orbit a central point. 2. To turn on an axis; rotate. See Synonyms at turn. 3. principally around Kali Laboratories, a company acquired in 2004. Both companies hold a number of ANDAs under their own name. The most recent drug to be approved is ondansetron, a version of Merck's Zofran. The company boosted its position in the US market in 2006, through the purchase of a number of drugs from Teva and IVAX IVAX Industrial Vax (Dec Computer) . This was mandated by the FTC FTC See Federal Trade Commission (FTC). as a condition of the merger between the latter two companies. Topics Covered Executive Summary Introduction Kali Laboratories Products Teva/IVAX Drugs Divested to Par Pharmaceutical Companies Par Pharmaceutical ANDA Approvals, 2002-06 Kali Laboratories ANDA Approvals, 2004-06 Recent Product Approvals Ondansetron Pravastatin. Companies gain meloxicam approvals Orchid gains cephalexin ANDA approval Amlodipine besylate tablets (tentative) Tranylcypromine sulphate tablets Miralax generic Financial results Par Pharmaceutical Financial Results 2001-05 (US$000s) Generic/Branded Revenues & Operating Income, 2003-05 (US$000s) Par Sales of Selected Generic Products, 2003-05 (US$000s) Major Developments Mergers, acquisitions and agreements AstraZeneca/Par enter agreement for generic version of Toprol-XL Spectrum Pharmaceuticals Sumatriptan injection Par divests FineTech Bradley and Par enter licensing agreement for Adoxa MN Pharmaceuticals Orchid Chemicals & Pharmaceuticals Litigation Reliant files patent infringement lawsuit against Par over Rythmol Unimed, Watson, Paddock and Par enter settlement agreements regarding AndroGel litigation Contact Details For more information, visit http://www.researchandmarkets.com/reports/c49747 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion